Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma
- PMID: 15836707
- DOI: 10.1111/j.1440-1746.2005.03726.x
Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma
Abstract
Background: Advanced hepatocellular carcinoma (HCC) in humans is characterized by hypervascularity. In the present study, the expressions of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF-2) and endostatin were analyzed in patients with chronic liver disease to clarify the effect of these major angiogenic factors.
Methods: Serum concentrations of VEGF, FGF-2 and endostatin in 24 patients with HCC, 16 patients with liver cirrhosis (LC) and 13 healthy volunteers were measured by enzyme-linked immunosorbent assay. The expression of VEGF in 21 surgically resected HCC samples was analyzed by immunohistochemistry, and that of VEGF isoforms in 15 HCC samples was assessed by reverse transcriptase-polymerase chain reaction (RT-PCR).
Results: Serum VEGF, FGF-2 and endostatin concentrations were significantly elevated in patients with HCC compared with healthy volunteers; but there was no significant difference between patients with HCC and those with non-HCC liver disease. Immunohistochemical analysis showed that VEGF protein was strongly expressed in both well-differentiated HCC cells and non-cancerous hepatocytes, whereas in moderately and poorly differentiated HCC the expression was stronger in the endothelial cells (EC) lining intratumor vessels than in the cancer cells. On RT-PCR for VEGF isoforms it was found that VEGF-121, VEGF-165 and VEGF-189 were expressed in all but one of the HCC samples and in all corresponding non-HCC samples.
Conclusions: The results suggest that VEGF, FGF-2, and endostatin concentrations are elevated prior to the emergence of HCC and that the distribution of VEGF changes dynamically during the development of HCC.
Similar articles
-
Serum endostatin predicts tumor vascularity in hepatocellular carcinoma.Cancer. 2002 Nov 15;95(10):2188-95. doi: 10.1002/cncr.10972. Cancer. 2002. PMID: 12412173
-
Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor.Hepatology. 1996 Mar;23(3):455-64. doi: 10.1053/jhep.1996.v23.pm0008617424. Hepatology. 1996. PMID: 8617424
-
Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma.Br J Surg. 2004 Oct;91(10):1354-60. doi: 10.1002/bjs.4594. Br J Surg. 2004. PMID: 15376182
-
Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.Kaohsiung J Med Sci. 2011 Aug;27(8):314-22. doi: 10.1016/j.kjms.2011.03.008. Epub 2011 May 8. Kaohsiung J Med Sci. 2011. PMID: 21802642
-
Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis.Br J Cancer. 2009 May 5;100(9):1385-92. doi: 10.1038/sj.bjc.6605017. Br J Cancer. 2009. PMID: 19401698 Free PMC article. Review.
Cited by
-
Plasma fibroblast growth factor 23 concentration is increased and predicts mortality in patients on the liver-transplant waiting list.PLoS One. 2013 Jun 25;8(6):e66182. doi: 10.1371/journal.pone.0066182. Print 2013. PLoS One. 2013. PMID: 23825530 Free PMC article.
-
Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science.Int J Clin Oncol. 2010 Jun;15(3):235-41. doi: 10.1007/s10147-010-0083-4. Epub 2010 May 27. Int J Clin Oncol. 2010. PMID: 20505971 Review.
-
Combination of Phenethyl Isothiocyanate and Dasatinib Inhibits Hepatocellular Carcinoma Metastatic Potential through FAK/STAT3/Cadherin Signalling and Reduction of VEGF Secretion.Pharmaceutics. 2023 Sep 27;15(10):2390. doi: 10.3390/pharmaceutics15102390. Pharmaceutics. 2023. PMID: 37896150 Free PMC article.
-
Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma.Mol Cell Biochem. 2013 Nov;383(1-2):103-12. doi: 10.1007/s11010-013-1759-7. Epub 2013 Aug 4. Mol Cell Biochem. 2013. PMID: 23912396
-
Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model.Gut. 2007 Feb;56(2):271-8. doi: 10.1136/gut.2005.088583. Epub 2006 Jun 29. Gut. 2007. PMID: 16809420 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical